A recombinant human adenovirus expressing the simian immunodeficiency virus Gag antigen can induce long-lived immune responses in mice Free

Abstract

Human adenovirus type 5 can be used as a vector to elicit immune responses to antigens expressed from heterologous DNA sequences incorporated into the viral genome, for example in mice immunized intraperitoneally. We have used a recombinant adenovirus which expresses the p55 antigen of simian immunodeficiency virus to evaluate the nature and longevity of the response elicited when administered to mice by alternative routes which translate more readily to larger animals and man. In C57Bl/6 mice immunized orally with a single dose of virus, a majority of the animals which showed evidence of responding to the immunogen by producing an anti-adenovirus response also pro-duced a plasma antibody response to Gag which persisted for more than 1 year and a Gag-specific cytotoxic T cell response that could be detected for at least 6 months. In a minority of similarly immunized responding animals, only a cytotoxic response to Gag was observed although both humoral and cellular responses to adenovirus antigens were seen; intranasal immunization produced a Gag- specific response similar to this latter pattern. These findings suggest that delivery of adenovirus recombinants orally or intranasally may be a useful strategy for eliciting long-term cytotoxic T cell memory responses in splenocytes to candidate vaccine antigens.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-78-5-991
1997-05-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/78/5/9152415.html?itemId=/content/journal/jgv/10.1099/0022-1317-78-5-991&mimeType=html&fmt=ahah

References

  1. Almond N., Page M., Mills K., Jenkins A., Ling C., Thorpe R., Kitchen P. 1990; The production and purification of PCR-derived recombinant simian immunodeficiency virus p27 gag; its use in detecting serological and T-cell responses in macaques. Journal of Virological Methods 28:321–326
    [Google Scholar]
  2. Bett A. J., Prevec L., Graham F. L. 1993; Packaging capacity and stability of human adenovirus type 5 vectors. Journal of Virology 67:5911–5921
    [Google Scholar]
  3. Both G. W., Lockett L. J., Janardhana V., Edwards S. J., Bellamy A. R., Graham F. L., Prevec L., Andrews M. E. 1993; Protective immunity to rotavirus-induced diarrhoea is passively transferred to newborn mice from naive dams vaccinated with a single dose of a recombinant adenovirus expressing rotavirus VP7sc. Virology 193:940–950
    [Google Scholar]
  4. Bourgault I., Villefroy P., Beyer C., Aubertin A.-M., Levy J.-P., Venet A. 1993; Cytotoxic T-cell response and AIDS-free survival in simian immunodeficiency virus-infected macaques. AIDS 7:S73–S79
    [Google Scholar]
  5. Brookes R., Bergmeier L. A., Mitchell E., Walker J., Tao L., Klavinskis L., Meyers N. J., Layton G., Adams S. E., Lehner T. 1995; Generation of diversity in the hierarchy of T-cell epitope responses following different routes of immunization with simian immunodeficiency virus protein. AIDS 9:1017–1024
    [Google Scholar]
  6. Caravokyri C., Pringle C. R., Leppard K. N. 1993; Human adenovirus type 5 recombinants expressing simian immunodeficiency virus macaque strain gag antigen. Journal of General Virology 74:2819–2824
    [Google Scholar]
  7. Daniel MD., Kirchoff F., Czajak S. C., Sehgal P. K., Desrosiers R. C. 1992; Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938–1941
    [Google Scholar]
  8. Dormont D., Legrand R., Cranage M., Greenaway P., Hunsmann G., Stahl-Hennig C., Rossi G., Verani P., Stott J., Kitchin P., Osterhaus A., Devries P., Kurth R., Norley S., Heeney J., Biberfeld G., Putkonen P. 1995; Protection of macaques against simian immuno-deficiency virus infection with inactivated vaccines: comparison of adjuvants, doses and challenge viruses. Vaccine 13:295–300
    [Google Scholar]
  9. Fooks A. R., Schadeck E., Liebert U. G., Dowsett A. B., Rima B. K., Stewart M., Stephenson J. R., Wilkinson G. W. G. 1995; High level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: induction of an MHC-1-restricted CTL response and protection in a murine model. Virology 210:456–465
    [Google Scholar]
  10. Gallichan W. S., Johnson D. C., Graham F. L., Rosenthal K. L. 1993; Mucosal immunity and protection after intranasal immunisation with a recombinant adenovirus expressing herpes simplex glycoprotein B. Journal of Infectious Diseases 168:622–629
    [Google Scholar]
  11. Gallimore A., Cranage M., Cook N., Almond N., Bootman J., Rud E., Silvera P., Dennis M., Corcoran T., Stott J., McMichael A., Gotch F. 1995; Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nature Medicine 1:1167–1173
    [Google Scholar]
  12. Ganne V., Eloit M., Laval A., Adam M., Trouve G. 1994; Enhancement of the efficacy of a replication-defective adenovirus-vectoredvaccine by the addition ofoil adjuvants. Vaccine 12:1190–1196
    [Google Scholar]
  13. Graham F. L., Smiley J., Russel W. C., Nairn R. 1977; Characteristics of a human cell line transformed by DNA from human adenovirus type 5. Journal of General Virology 36:59–72
    [Google Scholar]
  14. Hu S.-L. 1996; Recombinant subunit vaccines against primate lentiviruses. AIDS Research and Human Retroviruses 12:451–453
    [Google Scholar]
  15. Hu S.-L., Abrams K., Barber G. N., Moran P., Zarling J. M., langlois A. J., Kuller L., Morton W. R., Benveniste R. E. 1992; Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255:456–459
    [Google Scholar]
  16. Imler J.-P. 1995; Adenovirus vectors as recombinant viral vaccines. Vaccine 13:1143–1151
    [Google Scholar]
  17. Jacobs S. C., Stephenson J. R., Wilkinson G. R. 1992; High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: protection elicited in a murine model. Journal of Virology 66:2086–2095
    [Google Scholar]
  18. Klessig D. F., Grodzicker T. 1979; Mutations that allow human Ad2 and Ad5 to express late genes in monkey cells map in the viral gene encoding the 72k DNA binding protein. Cell 17:957–966
    [Google Scholar]
  19. Kruijer W., van Schaik F. M. A., Sussenbach J. S. 1981; Structure and organisation of the gene coding for the DNA binding protein of adenovirus type 5. Nucleic Acids Research 9:4439–4457
    [Google Scholar]
  20. Lehner T., Wang Y. F., Cranage M., Bergmeier L. A., Mitchell E., Tao L., Hall G., Dennis M., Cook N., Brookes R., Klavinskis L., Doyle C., Ward R. 1996; Protective mucosal immunity elicited by targeted iliac lymph-node immunization with a subunit SIV envelope and core vaccine in macaques. Nature Medicine 2:767–775
    [Google Scholar]
  21. Lubeck M. D., Davis A. R., Chengalvala M., Natuk R. J., Morin J. E., Molnar-Kimber K., Mason B. B., Bhat B. M., Mizutani S., Hung P. P., Purcell R. H. 1989; Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proceedings of the National Academy of Sciences, USA 86:6763–6767
    [Google Scholar]
  22. Lubeck M. D., Natuk R. J., Chengalvala M., Chanda P. R., Murthy K. K., Murthy S., Mizutani S., Lee S.-G., Wade M. S., Bhat B. M., Bhat R., Dheer S. K., Eichberg J. W., Davis A. R., Hung P. P. 1994; Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration. AIDS Research and Human Retroviruses 10:1443–1449
    [Google Scholar]
  23. McMichael A. J., Michie C. A., Gotch F. M., Smith G. L., Moss B. 1986; Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. Journal of General Virology 67:719–726
    [Google Scholar]
  24. Mittal S. K., Middleton D. M., Tikoo S. K., Babiuk L. A. 1995; Pathogenesis and immunogenicity of bovine adenovirus type 3 in cotton rats (Sigmodon hispidus). Virology 213:131–139
    [Google Scholar]
  25. Natuk R. J., Lubeck M. D., Chanda P. K., Chengalvala M., Wade M. S., Murthy S. C. S., Wilhelm J., Vernon S. K., Dheer S. K., Mizutani S., Lee S.-G., Murthy K. K., Eichberg J. W., Davis A. R., Hung P. P. 1993; Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. AIDS Research and Human Retroviruses 9:395–404
    [Google Scholar]
  26. Prevec L., Schneider M., Rosenthal K. L., Belbeck L. W., Derbyshire J. B., Graham F. L. 1989; Use of human adenovirus-based vectors for antigen expression in animals. Journal of General Virology 70:429–434
    [Google Scholar]
  27. Prevec L., Campbell J. B., Christie B. S., Belbeck L., Graham F. L. 1990; A recombinant human adenovirus vaccine against rabies. Journal of Infectious Diseases 161:27–30
    [Google Scholar]
  28. Prevec L., Christie B. S., Laurie K. E., Bailey M. M., Graham F. L., Rosenthal K. L. 1991; Immune responses to HIV-1 Gag antigens induced by recombinant adenovirus vectors in mice and rhesus macaque monkeys. Journal of Acquired Immune Deficiency Syndromes 4:568–576
    [Google Scholar]
  29. Rowland-Jones S. L., McMichael A. 1995; Immune responses in HIV-exposed seronegatives: have they repelled the virus?. Current Opinion in Immunology 7:448–455
    [Google Scholar]
  30. Top F. H., Grossman R. A., Bartelloni P. J., Segal H. E., Dudding B. A., Russell P. K., Buscher E. L. 1971; Immunisation with live types 7 and 4 adenovirus vaccines. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans. Journal ofInfectious Diseases 124:148–154
    [Google Scholar]
  31. Vaslin B., Le Grand R., Vogt G., Benveniste O., Gras G., Roques P., Stoeckel P., Salk P. L., Salk J., Dormont D. 1994; Induction of humoral and cellular immunity to simian immunodeficiency virus : what are the requirements for protection?. Vaccine 12:1132–1139
    [Google Scholar]
  32. Wesseling J. G., Godeke G-J., Schijns V. E. C. J., Prevec L., Graham F. L., Horzinek M. C., Rottier P. J. M. 1993; Mouse hepatitis virus spike and nucleocapsid proteins expressed by adenovirus vectors protect mice against a lethal infection. Journal of General Virology 74:2061–2069
    [Google Scholar]
  33. Wraith D. C., Vessey A. E., Askonas B. A. 1987; Purified influenza virus nucleoprotein protects mice from lethal infection. Journal of General Virology 68:433–440
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-78-5-991
Loading
/content/journal/jgv/10.1099/0022-1317-78-5-991
Loading

Data & Media loading...

Most cited Most Cited RSS feed